Healthy fear and clinical anxiety share many of the same symptoms. As such, the neural substrates of experimentally-induced fear have often been studied to better understand those of anxiety. We have done so using changes in the amplitude of the acoustic startle response as a behavioral measure. Indeed, the amplitude of the startle reflex can be modified by a variety of stimuli including conditioned fear cues (e.g., brief stimuli previously paired with shock -- [@R2]) and also, in rats, by sustained exposure to bright light -- a putative anxiety response to increased vulnerability ([@R42]).

Although fear-potentiated and light-enhanced startle are both disrupted by benzodiazepines and other anxiolytic compounds ([@R7]; [@R42]; [@R44]), the neuro-anatomical substrates of the two phenomena differ, with fear-potentiated startle requiring AMPA receptor activation in the central nucleus of the amygdala (CeA) but not the closely related bed nucleus of the stria terminalis (BNST), and light-enhanced startle requiring just the opposite -- i.e., AMPA receptor activation in the BNST but not the CeA ([@R43]). Based on these and other observations, we have suggested that the CeA and BNST may be key components of functionally distinct threat-response systems, with rapid-onset short-duration threat responses being mediated by rapid excitatory transmission in the CeA, and more slowly developing sustained responses being mediated by ionotropic and perhaps metabotropic receptor activity in the BNST (c.f., [@R47]). We have also suggested that BNST-dependent effects such as light-enhanced startle, which are typically characterized by a relatively slow onset and offset (e.g., compare [@R5]; with [@R8]) and which may occur in the absence of any extant threat at all, may be more closely related to anxiety than to stimulus-specific fear (c.f., [@R46]). If so, then pharmacological treatments that selectively interfere with BNST function might be especially useful for the treatment of at least some types of anxiety symptoms, and perhaps disorders.

In this regard, corticotropin releasing-factor (CRF) antagonists are particularly interesting. CRF-R1 protein and mRNA are abundant in the BNST but sparse in the CeA ([@R27]; [@R40]; [@R48]), and CRF infusions into the BNST ([@R22]) but not amygdala ([@R24]) increase startle amplitude. Moreover, the startle-enhancing effects of i.c.v. CRF infusions are blocked by excitotoxic BNST lesions and also by intra-BNST infusions of the CRF1/2 antagonist α-helical CRF~9-41~, but are not blocked by neurotoxic CeA lesions ([@R22]).

Consistent with the view that BNST-dependent threat responses are especially sensitive to CRF receptor blockade (e.g., relative to CeA-dependent responses), [@R8] found that i.c.v. α-helical CRF~9-41~ infusions non-monotonically disrupted light-enhanced startle but had no effect on fear-potentiated startle to a 3.7-sec conditioned fear stimulus (CS) at the same or a 5-fold higher dose. This may reflect a genuine difference in the involvement of CRF receptors in these two types of responses or, alternatively, preferential access of BNST neurons to i.c.v.-infused CRF, insofar as the BNST (e.g., unlike the CeA) lies immediately adjacent to the lateral ventricle. In fact, [@R35] reported that systemic administration of the selective CRF-R1 antagonist CP154,526 *did* disrupt fear-potentiated startle, [@R14] reported that α-helical CRF~9-41~ infusions into the caudal reticular formation also disrupted fear-potentiated startle, and [@R38] reported that i.c.v. α-helical CRF~9-41~ infusions did so as well (i.e., seemingly in direct contrast to the results reported by [@R8]). Although these studies suggest that fear-potentiated startle *can* be disrupted by CRF receptor antagonists under some circumstances, they are not inconsistent with the view that longer-duration BNST-dependent startle increases are *more* sensitive because in all but [@R8], the effect of the antagonist on BNST-dependent startle increases was not evaluated in parallel.

A primary goal of this study then was to directly compare the sensitivity of CeA-dependent fear-potentiated and BNST-dependent light-enhanced startle to systemic administration of the novel, potent, and selective nonpeptide CRF-R1 antagonist GSK876008 ([@R10]), after first evaluating in the same animals the effect of the same doses on an unambiguously CRF-mediated effect, CRF-enhanced startle.

Materials and Methods {#S1}
=====================

Animals {#S2}
-------

Adult (300-350 g at the time of arrival) Sprague-Dawley rats (Charles River; Raleigh, NC) were group-housed (4/cage) and a maintained on a 12-hr light/dark cycle with lights on at 0800 and free access to food and water. 45 female and 49 males were used for the primary experiment (i.e., in which each rat was tested first for CRF-enhanced startle, then for light-enhanced startle, and then for fear-potentiated startle). An additional 28 male and 28 female rats were used in a supplemental experiment in which rats were tested for fear-potentiated startle only. Both genders were used in these experiments because we wished to evaluate the reliability of our previous finding ([@R39]) that females show greater light-enhanced startle than males, and to see if similar differences would be observed with respect to CRF-enhanced startle, which is also BNST-dependent, but not fear-potentiated startle, which is not. All procedures were conducted in accordance with USDA, NIH, and Emory University guidelines for the care and use of laboratory animals.

Apparatus {#S3}
---------

Rats were trained and tested in four identical 8(L) × 15(W) × 15(H)-cm Plexiglas and wire mesh cages, each with four 6.0-mm diameter stainless steel floorbars.

Startle responses were evoked by 50-msec white-noise bursts generated by a Macintosh G3 computer sound file, amplified by a Radio Shack amplifier (100 Watt; Model MPA-200; Tandy, Fort Worth, TX), and delivered through Radio Shack Supertweeter speakers located 5 cm in front of each cage. Background noise (60 dB wideband) was provided by a General Radio (Concord, MA) Type 1390-B noise generator and delivered through the same speakers used for the startle stimulus. Startle response amplitudes were quantified using a PCB Piezotronics (Depew, NY) accelerometer (model U321AO2) affixed to the bottom of each cage. Displacement of the accelerometer by the rats\' startle response produced a voltage output that was integrated by a PCB Piezotronics signal conditioner (Model 483B21) and digitized by a GW Instruments (Somerville, MA) Instrunet device (Model 100B). Startle amplitude was defined as the maximum peak-to-peak voltage of the Instrunet\'s output during the first 200 msec after each noise burst, and was quantified in arbitrary units from 0.000 to 1.998 (linear scale).

Illumination for light-enhanced startle testing (150 lux), and for the CS during fear-potentiated startle testing (82 lux) was provided by Med Associates Inc. (Georgia, VT) PHM-258 fluorescent bulbs located 10 cm behind each cage. The footshocks used (0.5 sec, 0.4 mA) for fear conditioning were delivered through the floorbars and were generated by LeHigh Valley (Beltsville, MD) shock generators (model SGS-004).

The presentation and sequencing of all stimuli was under the control of a Macintosh G3 computer using custom-designed software (The Experimenter; Glassbeads Inc., Newton, CT).

Drugs and Drug Administration {#S4}
-----------------------------

GSK876008 was synthesized by the Medicinal Chemistry Department of GlaxoSmithKline Medicines Research Centre (Verona, Italy), prepared as a suspension in 0.5% (*w*/*v*) hydroxypropyl methylcellulose (HPMC), and administered *p.o.* at a volume of 2 ml/kg, and doses ranging from 0.1 mg/kg to 60 mg/kg. Previous findings indicate that GSK876008 shows a CNS bioavailability of 66% (58-73%, CL95) and a half life of 1.6 h (1.4-1.7 h CL95) following oral administration at 10 mg/kg, with exposure increasing linearly up to doses of 300 mg/kg ([@R10]). In vitro, GSK876008 shows a functional potency (pA~2~) of 7.14 ± 0.12 on recombinant human CRF1 receptors expressed in CHO cells, but is inactive on human CRF2 receptors or the CRF binding protein, or on 83 other G-protein coupled receptors, channels, enzymes and transporters up to a concentration of 10 μM ([@R10]).

CRF (human/rat) was purchased from Peninsula Laboratory (San Carlos, CA), dissolved in ACSF, and infused into the lateral ventricle (1 μg/5 μl/5 min) through 28-gauge injection cannulae (Model C313I; Plastics One, Roanoke, VA) using a pump-controlled Hamilton microsyringe. Injection cannulae were left in place for 60 s after the infusion was completed.

### General Design and Experimental Sequence {#S5}

Each rat in the primary study was tested sequentially (each test approximately one week apart) for CRF-enhanced, then light-enhanced, and then fear-potentiated startle after receiving one of several GSK876008 doses (0, 0.1, 0.3, 1, 3, 10, 30, or 60 mg/kg; p.o.). Each individual rat received the same dose for each of the three tests. Doses were selected based on previous findings that GSK876008 disrupts separation-induced vocalizations in rat pups at 30 and 60 mg/kg (*i.p.*), CRF-induced forepaw treading in gerbils at 10 and 30 mg/kg (*p.o.*), and anxiety-related behavior in the marmoset human threat test at 3, 10, and 30 mg/kg (*p.o.*) ([@R10]). An additional group of rats was tested for fear-potentiated startle without having first been tested for CRF- or light-enhanced startle.

Surgery {#S6}
-------

Rats were anesthetized with sodium pentobarbital (50 mg/kg, *i.p.*), injected with an analgesic dose of buprenorphine (0.01 mg/kg, *s.c.*; repeated approximately 12 hrs post-surgery), and with atropine (0.04 mg/kg, *s.c.*) to prevent pulmonary congestion. Using standard stereotaxic procedures, 22-gauge guide cannulae (model C313G, Plastics one, Roanoke, VA) were lowered into the lateral ventricle (AP = −0.4, DV = −5.5, ML = + 1.2 mm from bregma; flat-skull position), and cemented in place using Cranioplastic Powder (Plastic One). Stainless steel wires, cut so as to protrude approximately 1 mm from the guide cannulae\'s tips, were inserted to maintain patency, and stainless steel lock nuts screwed onto the top to prevent rats from chewing the cannulae and dislodging the wire.

CRF-Enhanced Startle {#S7}
--------------------

7-10 days after surgery, rats were acclimated to the experimental context and stimuli during an initial test consisting of 30 95-dB noise bursts (interstimulus interval \[ISI\] = 30 sec). On the following day, rats received a pre-infusion baseline startle test identical to that just described and, immediately thereafter, GSK876008 (0.1, 0.3, 1, 3, 10, 30, or 60 mg/kg) or vehicle. Two hours later, they received an intra-ventricular infusion of either CRF (1 μg) or ACSF (5 μl/5 min) followed 1 hr later by a 2^nd^ startle test consisting of 120 95-dB noise bursts. One week later, this process was repeated except that rats that had initially received CRF now received ACSF and vice versa (for both tests, they received the same dose of GSK876008).

For each rat, ACSF and CRF proportion of pre-infusion baseline scores (i.e., post-infusion/pre-infusion startle amplitude) were calculated. CRF-enhanced startle was expressed as a percent change score according to the formula ((CRF proportion of baseline score -- ACSF proportion of baseline score)/ACSF proportion of baseline score) × 100.

Light-Enhanced Startle {#S8}
----------------------

No less than 1 week after the final CRF-enhanced startle test, rats received another acclimation session and, on the following day, the first of two light-enhanced startle tests (one week apart). Each of the two tests was composed of two consecutive phases during which rats received 30 startle-eliciting noise bursts. For one of these tests, phase I noise bursts were presented in the dark and phase II noise bursts in the light. For the other test (counterbalanced), phase I and II noise bursts were both presented in the dark. Two hours prior to each test, rats were given the same dose of GSK876008 (0, 0.1, 0.3, 1, 3, 10, 30, or 60 mg/kg) that they had previously received prior to CRF-enhanced startle testing.

For each rat, dark-\>dark and dark-\>light proportion of baseline scores were calculated (i.e., phase II startle amplitude/by phase I startle amplitude). Light-enhanced startle was expressed as a percent change score according to the formula (dark-\>light proportion of baseline score -- dark-\>dark proportion of baseline score)/dark-\>dark proportion of baseline score) × 100.

Fear-Potentiated Startle {#S9}
------------------------

Approximately 1 week later, rats received on each of two consecutive days, 10 pairings of a 3.7-sec light and co-terminating footshock (intertrial interval = 3, 4, or 5 min, randomly ordered). Twenty-four hours later, they received a brief fear-potentiated startle test consisting of 30 95-dB noise bursts with 5 of the final 10 (randomly ordered) occurring 3.2 sec after CS onset. Data from this initial test were used to verify that the mean fear-potentiated startle level in the different treatment groups was similar before drug administration and, in the supplemental experiment described below, to assign rats to different treatment groups to ensure that it was. Twenty-four h later, they again received GSK876008 (0, 0.1, 0.3, 1, 3, 10, 30, or 60 mg/kg) and 2 hours later a 2^nd^ fear-potentiated startle test consisting of 60 95-dB noise bursts, of which 30 were presented in the presence and 30 in the absence of the CS.

As described in the results section, GSK876008 had no obvious effect on fear-potentiated startle to the 3.7-sec CS in this, the primary experiment. To ensure that this was not due to prior drug exposure (i.e., during CRF- and light-enhanced startle testing), the effect of 0, 3, and 10 mg/kg GSK876008 was re-evaluated in an additional group of 12 male and 12 female rats that had not previously received drug (or been tested for CRF- or light-enhanced startle). We also considered the possibility that drug effects on fear-potentiated startle might be more apparent in rats trained with weaker conditioning procedures. Therefore, another group (16 males and 16 females) was trained using a single day of conditioning consisting of 10 pairings of very weak 0.25-mA footshocks and light (i.e., versus 2 days of 10 pairings with 0.4 mA footshocks).

Fear-potentiated startle was expressed as percent change scores according to the formula (startle amplitude on CS trials -- startle amplitude on noise burst alone trials)/startle amplitude on noise burst alone trials) × 100.

Statistical Analyses {#S10}
--------------------

Percent potentiation scores, calculated as described above, were screened for outliers using the inter-quartile range test, which rejects scores laying more than 3 times the interquartlle range (i.e., Q3-Q1) above the 3^rd^ quartile or below the 1^st^. The remaining scores were analyzed with ANOVA, using Dose and Gender as between-subjects factors, and the shape of the dose-response curves evaluated with linear and quadratic contrast tests. The scores for each dose were obtained from a minimum of two replications and were normalized to the mean potentiation score of vehicle-treated rats, which were included in each run, according to the formula (individual percent potentiation score -- mean vehicle percent potentiation score). For illustrative purposes, the mean level of potentiation in the control group was added to these difference scores.

To assess drug effects on baseline startle, each rats mean startle amplitude under the influence of the antagonist was calculated from the 2 pre-infusion and 2 dark phase I tests of CRF- and light-enhanced startle testing, respectively (i.e., after GSK876008 administration but before the startle potentiating treatment of either CRF or light). These startle scores were then assessed with ANOVA using DOSE and GENDER as factors, and baseline startle amplitude without the antagonist (from the initial drug-free acclimation session) as a covariate. 'Baseline' startle from the fear-potentiated startle test (i.e., noise alone test trials) was not included in this analysis because fear that may have incidentally conditioned to the shock context and influenced startle amplitude would have confounded such an analysis.

In fact, although this study was not designed with the specific intent of evaluating GSK876008 effects on context conditioning (a phenomenon that we have typically found to be quite modest), such an analysis was possible. To do so, the mean startle amplitude of each rat to the 95-dB noise alone trials of the fear-potentiated startle test (i.e., those that were presented in the *absence* of the explicit visual CS) was divided by that rat\'s mean startle amplitude to the 95-dB noise bursts during phase I of the preceding light-enhanced startle test (i.e., the most recent test trials which occurred in the dark before fear conditioning). For both conditions then, rats were tested in the dark after having received the same dose of GSK876008. The essential difference was that one set of data was collected prior to, and another set of data was collected after rats had received footshocks in the test context. The resulting percent change scores were analyzed as described previously for fear-potentiated startle to the phasic CS.

All analyses were conducted using SPSS software (v13.0.0; Chicago, IL). The criterion for significance set at *p* \< .05 (two-tailed).

Results {#S11}
=======

Baseline Startle Amplitude {#S12}
--------------------------

ANOVA on baseline startle amplitude following GSK876008 administration ([Table I](#T1){ref-type="table"}) indicated a small but significant effect of GENDER, F(1, 77)=13.94, with the mean startle amplitude of females being approximately 23% less than males (perhaps owing to their slightly lower weight), and also of baseline startle amplitude prior to GSK876008 administration as a covariate, F(1, 77)=48.39, but not of DOSE (*p*=0.189). That GSK876008 did not significantly affect baseline startle amplitude is consistent with our subjective observations of the animals\' behavior that drug-injected rats did not exhibit overt motoric effects such as hyperactivity or ataxia that would have affected startle amplitude or its potentiation by CRF, light, or fear.

CRF-Enhanced Startle {#S13}
--------------------

Of the 94 rats that were tested for CRF-enhanced startle, the data from 5 were excluded due to problems with the infusion (e.g., clogged cannulae), and the data from 4 others were excluded based on outlier criterion. Although these atypical responders -- with percent potentiation scores of 599% (0 mg/kg), 964% (0.3 mg/kg), 491% (3 mg/kg), and 624% (60 mg/kg) -- are potentially quite interesting on an individual basis, inclusion of their scores would grossly distort the group means and variability measures, and violate assumptions of normality required for analyses of the more representative animals presented below.

CRF-enhanced startle for the included rats is shown in [Figure 1](#F1){ref-type="fig"}. ANOVA indicated a significant effect of GSK876008 DOSE, *F*(7, 69)=3.36, but not of GENDER, *F*(1, 69)=2.28, *p*=0.136, with a significant fit of the dose-response curve to a linear trend, *t*(77)=3.94.

Light-Enhanced Startle {#S14}
----------------------

Data were collected from 89 rats. Four rats that had been tested for CRF-enhanced startle were euthanized prior to light-enhanced startle testing due to lost headcaps, and the data from one rat was lost due to a technical problem. There were no outliers. The effect of GSK876008 on light-enhanced startle is shown in [Figure 2](#F2){ref-type="fig"}. Although there was not a significant DOSE or GENDER effect overall, contrast tests indicated that the dose-response function was significantly fit to a quadratic trend, *t*(81)=2.58, thereby replicating the pattern previously reported by [@R8] who used i.c.v. infusions of α-helical CRF~9-41~.

Fear-Potentiated Startle {#S15}
------------------------

For the primary experiment, data were collected from 90 rats (as previously indicated, 4 of the initial 94 rats were euthanized due to lost headcaps). There were no outliers. ANOVA on fear-potentiated startle (i.e., from test trials without the 3.7-sec CS to those with the CS - [Figure 3](#F3){ref-type="fig"}) revealed no significant effects -- either of GENDER or of DOSE. ANOVA on startle increases from phase I of the light-enhanced startle test which most recently preceded fear-potentiated startle testing to the noise alone test trials of the fear-potentiated startle test itself (i.e., possible context-potentiated startle -- [Figure 4](#F4){ref-type="fig"}) also found no effect of DOSE or GENDER, but did indicate a significant fit of the dose-response curve to a linear trend, *t*(23.9)=2.87, *p*=.009 without assuming equal variances and *t*(79)=1.95, *p*=.055 assuming equal variances. For this analysis, the data from a single outlier (285% pre- to post-shock startle increase) was excluded from the 10 mg/kg group. The quadratic trend was *not* significant, but it is perhaps noteworthy in view of the U-shaped dose-response function for light-enhanced startle that pre- to post-shock startle increases in the 60 mg/kg group were higher than in the next 3 lower dose groups but not markedly lower than those in the vehicle group. In fact, there was some evidence for a bimodal distribution at 60 mg/kg with 3 high scores of 172%, 172%, and 181%, and 4 low scores of 9%, 23%, 38%, and 81%.

Supplemental Analyses of CRF-Enhanced, Light-Enhanced, and Fear-Potentiated Startle Scores in Groups with Equated Baseline Startle Levels {#S16}
-----------------------------------------------------------------------------------------------------------------------------------------

Although GSK876008 did not significantly influence baseline startle amplitude, there *were* nominal group differences due to random variation. To ensure that these differences did not somehow contribute to the apparent drug effects on CRF- and light-enhanced startle, and the non-effect on fear-potentiated startle, the analyses presented above were repeated after having equated the different groups for baseline startle amplitude by eliminating potentiation scores from rats with the lowest or highest baseline startle scores. To do this, the potentiation score of the rat with the lowest baseline startle amplitude was dropped from the group with the lowest mean baseline level, and the potentiation score of the rat with the highest baseline startle amplitude was dropped from the group with the highest mean baseline level. This procedure was repeated (separately for each paradigm) until the mean baseline level of the highest group was no more than 20% greater than that of the lowest group (the criteria was set in advance). This resulted in the elimination of 10 data-points from the CRF-enhanced startle analysis (low group = 0.53, high group = 0.64), 7 from the light-enhanced startle analysis (low group = 0.63, high group = 0.76), and 5 from the fear-potentiated startle analysis (low group = 0.92, high group = 1.09) of the primary study. The results of these analyses were not substantively different from the same analyses performed on the full dataset. That is, ANOVA indicated a significant effect of DOSE, *F*(7, 73)=2.51, for CRF-enhanced startle with a significant linear trend *t*(66)=3.53; no main effect of DOSE for light-enhanced startle but a significant fit of the dose-response curve to a quadratic trend, *t*(74)=2.14, and no significant effect of any sort for fear-potentiated startle to the 3.7-sec visual CS.

Analysis of Fear-Potentiated in Drug-Naïve Rats with Strong versus Weak Fear Conditioning {#S17}
-----------------------------------------------------------------------------------------

The effect of 3 and 10 mg/kg GSK876008 (i.e., doses that maximally disrupted light-enhanced startle and completely blocked CRF-enhanced startle) was re-evaluated in a new group of rats using standard as well as weak conditioning procedures. GSK876008 again failed to disrupt fear-potentiated startle, but appeared instead to enhance fear-potentiated startle at the 3 mg/kg dose ([Figure 5](#F5){ref-type="fig"}). Statistically, ANOVA indicated significant main effects of PROTOCOL (i.e., weak versus strong training), *F*(1, 43)=9.10, and also of DOSE, *F*(2, 43)=3.57, with the dose-response curve significantly fit to a quadratic trend, *t*(52)=2.24.

Discussion {#S18}
==========

Previous findings indicate that CRF-enhanced startle is mediated by the activation of CRF receptors within the BNST ([@R22]). Other findings indicate that light-enhanced but not fear-potentiated startle is also dependent on the BNST, whereas fear-potentiated but not light-enhanced startle is dependent on AMPA receptor-mediated transmission in the CeA (e.g., [@R43]). These dissociations suggest the existence of two functionally distinct fear/anxiety systems, and raise the possibility that BNST-dependent anxiety may be especially sensitive to CRF-R1 blockade. That possibility was evaluated here using the novel, potent, and selective CRF-R1 antagonist GSK876008.

When delivered 2 hrs prior to CRF infusions and 3 hrs prior to testing, GSK876008 dose-dependently disrupted CRF-enhanced startle, completely blocking the effect at GSK876008 doses of 10 mg/kg and higher. These results are consistent with those of [@R30]; [@R31] who found that systemic injections of the selective CRF-R1 antagonists NBI-30775 or R121919 significantly attenuated CRF-enhanced startle in mice, and with those of [@R35] who found that systemic injection of the CRF-R1 antagonist CP-154,526 blocked CRF-enhanced startle in rats. At least in mice, CRF2 receptors appear to play a relatively minor role -- perhaps augmenting the effect of CRF1 receptors, but having little if any effect on startle by themselves ([@R30]; [@R31]).

Light-enhanced startle was also disrupted by GSK876008 and appeared to be more sensitive to lower GSK876008 doses than CRF-enhanced startle. This difference in sensitivity most likely reflects the greater difficulty in overcoming behaviors produced by pharmacological CRF administration compared to physiological CRF release. Our results indicated a U-shaped dose-response function, mirroring very closely the results of [@R8] who found that i.c.v. infusions of 5 but not 25 μg α-helical CRF~9-41~ also disrupted light-enhanced startle. In principle, nonmonotonic dose-response curves obtained with α-helical CRF~9-41~ could reflect antagonist binding to the CRF binding protein (CRF-BP), which might then lead to an increase in free CRF ([@R1]). This would not explain our results however because GSK876008 is a non-peptide antagonist that does not bind to CRF-BP (tested at concentrations up to 10 μM -- D. Trist, unpublished data). Nor does it account for the fact that monotonic dose-response curves have been obtained with this compound in several other paradigms including CRF-induced gerbil forepaw treading (up to 30 mg/kg, p.o.), the human-threat tests in marmosets treading (up to 30 mg/kg, p.o.), and the separation-induced vocalization tests in rat pups (up to 60 mg/kg, *i.p.*) ([@R10]). An alternative account for the dose-response function obtained with light-enhanced startle is presented at the end of this section.

Although [@R39] and [@R6] have both found light-enhanced startle to be greater in female than in male rats, gender did not significantly influence light-enhanced startle in the current study. This suggests that the effect of gender on light-enhanced startle is unreliable or, alternatively, not robust against seemingly minor procedural variations. For example, in our experience, female rats are noticeably more reactive to handling, and more active in general, compared to male rats. Such reactivity may promote light-enhanced startle, but wane with repeated testing as the animals habituate to handling and the general experimental procedures. Indeed, there was some evidence for this in the baseline startle data, which decreased more rapidly in females (from 1.03 to 0.8 to 0.6) than in males (1.09 to 1.11 to 0.83) from the initial acclimation session to the CRF- and then light-enhanced startle test sessions. Perhaps then, these inconsistently observed gender differences with respect to light-enhanced startle are more apparent in experimentally-naïve rats.

In contrast to the disruptive effects on CRF- and light-enhanced startle, but consistent with results from several other studies that used other CRF receptor antagonists and different routes of administration ([@R6]; [@R22]; and see unpublished observations referred to in [@R29]), we found no evidence that GSK876008 disrupted fear-potentiated startle to the 3.7-sec visual CS. In fact, GSK876008 dose-dependently augmented fear-potentiated startle to the visual CS in the supplemental experiment. This is consistent with other observations from our laboratory that GSK876008 also augments, albeit inconsistently, fear-potentiated startle to short-duration white noise and clicker CSs (Walker, Miles, and Davis, in preparation).

Although GSK876008 did not affect baseline startle, there *were* nominal, pre-existing between-group differences. We are confident however that these did not contribute to between-group differences in potentiation scores. First, the statistical analyses presented earlier are based on percent change scores. We have previously shown that when fear levels remain constant, percent change scores also remain constant, even across baseline differences (e.g., due to individual variability, startle probe intensity, or drug manipulations) far greater than those noted here ([@R45]). Second, even though the general pattern of between-group differences in baseline startle was constant across the 3 paradigms, the general pattern of potentiation scores was not -- with the dose of GSK876008 related monotonically to CRF-enhanced startle, non-monotonically to light-enhanced startle, and not at all to fear-potentiated startle in the primary experiment. Perhaps most compelling, when the same analyses were repeated after equating the different groups for baseline startle amplitude (i.e., by culling out the lowest responders in low-baseline groups and the highest responders in high baseline groups), the outcomes of the statistical tests were not substantively altered.

In our view, one of the most important aspects of the current study is the side-by-side comparison of GSK876008 effects on light-enhanced versus fear-potentiated startle. As in [@R8], our results clearly indicate that the two types of responses -- although superficially identical (i.e., both being an increase in startle to a visual stimulus) -- *can* be pharmacologically dissociated. In the case of our results, this dissociation cannot readily be attributed to differential access to relevant receptor populations because the antagonist was administered orally. At a minimum then, the different effects of GSK876008 on fear-potentiated versus light-enhanced startle indicate a differential sensitivity to CRF-R1 blockade. The fact that fear-potentiated startle, with either strong or weak training, was not disrupted but actually enhanced in some animals suggests to us a more fundamental dissociation.

From a neuroanatomical perspective, we believe this fundamental dissociation may be related to the dependency of light-enhanced startle on the BNST and of fear-potentiated startle on the CeA. Functionally, we have suggested that these two brain areas may be preferentially involved in long- versus short-duration threat responses, respectively (c.f., [@R47]) -- a view consistent with recent findings from [@R41] who showed that BNST lesions block conditioned suppression to 10- but not 1-min clicker CSs, and from [@R36] who showed that BNST lesions disrupt freezing and corticosterone responses to a 5 min context CS but not to a 20-sec tone CS (and see also [@R28], for BNST inactivation effects on cardiovascular responses to a context CS).

We did not design our study with the specific intent of assessing context conditioning, but the design of experiment 1 did allow for such an analysis. The results of that analysis are consistent with the view that GSK876008 also disrupted context-potentiated startle. Effects of CRF receptor blockade on context-potentiated startle have not, to our knowledge, been previously reported, although effects on context CS-induced freezing have (e.g., [@R9]; [@R17]; [@R21]). We emphasize the point that in the same animals in which GSK876008 appeared to disrupt context-potentiated startle, it clearly did not block fear-potentiated startle to the 3.7-sec CS. Because context discrimination controls were not included in our study, we cannot exclude the possibility that the pre- to post-shock startle increases were non-associative (e.g., shock-induced sensitization). However, because long-lasting shock-induced sensitization of the startle response also appears to be a BNST-dependent effect ([@R15], Walker & Davis, in preparation), that interpretation would also be consistent with the view that BNST-dependent startle increases, and sustained threat responses more generally, are especially sensitive to CRF receptor blockade. In fact, there appears to be a growing list of behavioral effects ranging from social defeat (e.g., [@R19]; [@R20]) to learned helplessness ([@R16]; [@R25]) to stress-induced reinstatement of drug-seeking behavior ([@R13]), for which susceptibility to BNST manipulations appears to be predictive of susceptibility to CRF receptor blockade. In addition, [@R33] and [@R23] have now reported anxiogenic effects of direct infusions into the BNST of CRF receptor agonists. If then, clinical anxiety or a subset of anxiety disorders were shown to involve either normal or dysregulated BNST activity, then CRF-R1 antagonists might be especially effective in alleviating their symptoms.

The complementary roles of the CeA and BNST, and the dependence of responses mediated by the latter on CRF, offer one possible explanation for the non-monotonic disruptive effect of CRF receptor blockade on light-enhanced startle seen here and elsewhere ([@R8]) and perhaps also for the non-monotonic facilitatory effect observed less consistently with respect to fear-potentiated startle ([@R46], [fig. 4](#F4){ref-type="fig"}, and present results). As depicted in [Figure 6](#F6){ref-type="fig"}, we believe that threat-encoding neurons project to both the CeA and the BNST, activating the former (CeA) rapidly and the latter (BNST) more slowly. We also hypothesize that the BNST sends an inhibitory signal to the phasic fear system. In fact, the BNST does send a substantial projection to the specific part of the CeA ([@R11]; [@R12]; [@R37]) thought to mediate phasic startle increases (e.g., [@R3]; [@R32]). Although the influence of this projection on medial CeA neurons is uncertain, anatomical ([@R18]) and electrophysiological ([@R4]; [@R18]) findings suggest that *lateral* CeA neurons, which are more closely affiliated with the BNST and a major source of its CRF input (e.g., [@R34]), do inhibit medial CeA neurons.

In response to a sustained threat stimulus then, the initial effect on startle would be mediated by direct and indirect projections from the medial CeA to brainstem areas that mediate the basic startle reflex. During a sustained threat signal, as CRF is released into the BNST and its neurons gradually come on line, it too would influence startle amplitude by way of it\'s own projections to these same brainstem areas. This increase in the BNST\'s activity would be accompanied by a concurrent decrease in the medial CeA\'s role, due to active inhibition by the BNST. If however, the BNST were to be inactivated (e.g., by high doses of a CRF receptor antagonist), then the inhibitory signal to the CeA would be lost, allowing CeA neurons to once again participate in the behavioral response. This then could generate a U-shaped dose-response function such as that observed with light-enhanced startle, assuming that the behavioral effect of the inhibitory output to CeA neurons was more resistant to disruption than the behavioral effect of the CeA\'s modulatory outputs to the brainstem. That is, at low doses the CRF-R1 antagonist would block enough receptors in the BNST to decrease light-enhanced startle but not enough to disinhibit the CeA. At higher doses, the CRF-R1 antagonist would prevent both effects, allowing CeA neurons to once again mediate startle increases, this time to sustained light. Importantly, disinhibition would not result in a U-shaped dose-response function for CRF-enhanced startle, or other behaviors that are independent of the CeA, because in these cases, with no signal impinging on the CeA, there would be nothing to disinhibit. The model also predicts that in cases where there was already some degree of tonic BNST activity (either evoked or spontaneous), inactivation might actually augment responses to phasic threat signals. Indeed, this very effect has been reported by [@R26] who found that direct infusions of the GABA-A agonist muscimol into the BNST markedly potentiated fear-potentiated startle to a 3.7-sec visual CS. All of this is very speculative of course, and presented primarily as one possible explanation for the non-monotonic dose-response curve reported here and in other studies, and as a conceptual framework for the design of future experiments.

Overall, these findings add to a growing body of evidence arguing for a fundamental distinction between two types of threat responses -- functionally characterized, perhaps, by response duration, mediated by unique anatomical substrates, and distinguished by unique pharmacological vulnerabilities.
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![GSK876008 significantly (*p*=.004) disrupted CRF-enhanced startle with a significant fit of the dose-response curve to a linear trend (p=.000). GSK876008 was given orally 3 hr prior to testing. CRF (1 μg) or ACSF was infused into the lateral ventricle 1 hr prior to testing.](nihms383893f1){#F1}

![GSK876008 disrupted light-enhanced startle with a U-shaped dose-response curve, which was significantly fit to a quadratic trend, *t*(81)=2.58.](nihms383893f2){#F2}

![GSK876008 did not significantly influence fear-potentiated startle to a 3.7-sec visual CS in the same rats in which GSK876008 had been found to disrupt CRF- and light-enhanced startle.](nihms383893f3){#F3}

![The percent change in startle amplitude from phase I of the most recent light-enhanced startle test (i.e., startle to 95-dB noise probes presented in the dark after administration of the CRF-R1 antagonist, but *prior* to context-shock pairings) to startle amplitude during the noise alone trials of the fear-potentiated startle test (i.e., startle to 95-dB noise probes, in the dark, after administration of the CRF-R1 antagonist, 48 hr *after* context-shock pairings) is shown. GSK876008 dose-dependently disrupted the increase in responding, according to a linear trend (*p*=.009, without assuming equal variance).](nihms383893f4){#F4}

![In this experiment, the effect of GSK876008 was tested in experimentally-naïve rats that had received either standard or weak fear conditioning. As before, the CRF-R1 antagonist did not disrupt fear-potentiated starlte but, in this experiment, actually augmented potentiation to the 3.7-sec visual CS at the 3 mg/kg dose (quadratic trend, *p* \< .05).](nihms383893f5){#F5}

![Schematic drawing illustrating hypothetical involvement of the CeA and BNST in short- and long-duration startle increases, and of the functional relationship of these two areas with one another. In this model, the CeA (specifically, the medial subdivision) responds immediately to neural activity which signals threat, whereas the BNST responds more slowly, perhaps requiring the sustained activation of CRF receptors. Once on-line however, threat-elicited responses such as increased startle are mediated by the BNST, whose neurons then inhibit the CeA neurons which mediate the initial response. if the BNST were taken off-line (e.g., with sufficient CRF receptor blockade), then according to this model the CeA should once again be free to respond. Open circles and solid lines indicate active neurons and connections; gray circles and dashed lines indicate inactive or suppressed neurons and connections.](nihms383893f6){#F6}

###### 

Raw startle values (group means) from each of the three paradigms in the primary experiment (open cells). Shaded cells indicate mean percent-of-baseline measures (e.g., post-infusion divided by pre-infusion × 100, in the case of CRF-enhanced startle). These values are based on the mean of the individual animal\'s percent-of-baseline scores and are, therefore, close but not exactly equivalent to the percent of baseline score which would be calculated from the group mean startle values shown in the unshaded cells.

  Dose (mg/kg)   CRF-Enhanced Startle Tests   Light-Enhanced Startle Tests   Fear-Potentiated Startle Test                                                                             
  -------------- ---------------------------- ------------------------------ ------------------------------- ------ ------ ----- ------ ------ ----- ------ ------ ----- ------ ------ -----
  0              0.78                         0.6                            78                              0.82   1.05   137   0.67   0.59   91    0.68   0.77   118   0.92   1.54   176
  0.1            0.65                         0.44                           68                              0.73   0.9    139   0.53   0.59   109   0.7    0.82   124   1.06   1.82   173
  0.3            0.85                         0.61                           74                              0.78   1.22   174   0.7    0.79   124   0.61   0.77   136   1      1.79   196
  1              1.18                         1.23                           104                             1.29   2.38   187   0.93   0.93   92    1.08   1.13   101   1.18   2.05   164
  3              1.14                         0.95                           81                              1.37   0.96   79    0.88   0.71   80    0.99   0.87   90    1.09   1.61   143
  10             1.16                         0.82                           71                              1.15   0.98   88    0.71   0.76   130   0.74   0.72   104   1.12   1.67   156
  30             1.06                         0.71                           65                              1.32   1.14   72    0.92   0.75   83    1.09   0.96   86    1.02   1.82   178
  60             1.15                         0.61                           56                              1.35   0.91   69    0.59   0.49   81    0.58   0.63   111   0.69   1.03   156
